Cargando…
Combating HIV resistance – focus on darunavir
Darunavir is a second-generation protease inhibitor designed to have antiviral efficacy against HIV-1 isolates harboring multiple resistance mutations to protease inhibitors. Pivotal trials conducted in treatment-experienced HIV-infected individuals have demonstrated significantly greater virologica...
Autor principal: | Tremblay, Cécile L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2621389/ https://www.ncbi.nlm.nih.gov/pubmed/19209258 |
Ejemplares similares
-
Role of darunavir in the management of HIV infection
por: Lascar, R Monica, et al.
Publicado: (2009) -
Structures of Darunavir-Resistant HIV-1 Protease
Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014) -
Profile of darunavir in the management of treatment-experienced HIV patients
por: Wolfe, Cameron, et al.
Publicado: (2009) -
Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021) -
Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
por: Dobroszycki, Joanna, et al.
Publicado: (2011)